# US 2019/0314342 A1 · Method for treating demyelinating neuropathy with biotin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314342 A1
- Document ID: US20190314342A1
- Status: Published application
- Kind: A1
- Application number: 16/451,654
- Filed: 2019-06-25
- Published: 2019-10-17
- Earliest claimed: 2015-03-26
- Assignees: Medday Pharmaceuticals
- Applicants: MedDay Pharmaceuticals
- Inventors: Frédéric SEDEL
- Web page: https://patentgrep.com/patent/US20190314342A1

## CPC

- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the use of biotin for treating Amyotrophic Lateral Sclerosis, as well as demyelinating peripheral neuropathies and Neuromyelitis optica (NMO).

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for the treatment of a demyelinating neuropathy, comprising administering to a patient in need thereof a composition comprising an amount of biotin sufficient to treat said demyelinating neuropathy.

### Claim 22 (depends on 21)

The method of claim 21, wherein the demyelinating neuropathy is a peripheral demyelinating neuropathy.

### Claim 23 (depends on 21)

The method of claim 21, wherein the demyelinating neuropathy is a demyelinating neuropathy associated with immunoglobulin M (lgM) monoclonal gammopathy and antibodies against myelin-associated glycoprotein (MAG), typical chronic inflammatory demyelinating polyradiculoneuropathy, atypical chronic inflammatory demyelinating polyradiculoneuropathy, Charcot Marie Tooth la disease and Guillain-Barre syndrome.

### Claim 24 (depends on 21)

The method of claim 21, wherein the demyelinating neuropathy is neuromyelitis optica.

### Claim 25 (depends on 21)

The method of claim 21, wherein the demyelinating neuropathy is amyotrophic lateral sclerosis.

### Claim 26 (depends on 21)

The method of claim 21, wherein a daily amount of biotin administered to the patient is between 50 and 700 mg.

### Claim 27 (depends on 21)

The method of claim 21, wherein a daily amount of biotin administered to the patient is at least 100 mg.

### Claim 28 (depends on 21)

The method of claim 21, wherein a daily amount of biotin administered to the patient is at least 150 mg.

### Claim 29 (depends on 21)

The method of claim 21, wherein a daily amount of biotin administered to the patient is between 100 and 300 mg.

### Claim 30 (depends on 21)

The method of claim 21, wherein the composition is in a form suitable for oral administration.

### Claim 31 (depends on 21)

The method of claim 21, wherein the composition is in the form of gel capsules, tablets (optionally film-coated), lozenges or pills.

### Claim 32 (depends on 21)

The method of claim 21, wherein the composition comprises excipients and biotin as the sole active ingredient.

### Claim 33 (depends on 21)

The method of claim 21, wherein the composition is in a form suitable for injectable administration.

### Claim 34 (depends on 21)

The method of claim 21, wherein the composition is in a form of a slow release composition.

### Claim 34 (depends on 21)

The method of claim 21, wherein the treatment with biotin has a duration of at least 3 months.

### Claim 35 (depends on 21)

The method of claim 21, wherein the treatment with biotin has a duration of at least 6 months.

### Claim 36 (depends on 21)

The method of claim 21, wherein the treatment with biotin has a duration of at least one year.

### Claim 37 (depends on 21)

The method of claim 21, wherein the treatment includes simultaneous, separate or sequential administration of one or more active ingredients in addition to biotin.

### Claim 38 (depends on 37)

The method of claim 37, wherein the one or more active ingredients riluzole, baclofen, diazepam trihexyphenidyl, amitriptyline, corticosteroids, plasmapheresis azathioprine, mycophenolate mofetil, rituximab, mitoxantrone, glatiramer acetate, intravenous immunoglobulin (IVIG), and/or cyclophosphamide.

### Claim 39

A composition comprising an amount of biotin sufficient to treat a demyelinating neuropathy.
